GDT can be used for: Priority access to high-end curative diabetes tourism packages Payment for medical tourism services in the UAE, Palau, and Japan Purchase of 5-ALA supplements and formulations Biomarker testing for DSC detection Online consultations with specialist physicians Additionally, 20% of tokens used for medical services are burned to reduce supply.
GDT is a pure utility token directly tied to real-world services such as curative diabetes tourism, biomarker testing, and specialist consultations. Unlike speculative tokens, it is backed by a scientific project targeting complete remission of diabetes through HDAC inhibitors, 5-ALA, and Biozipcode™ drug delivery technology. It is not a security and offers no dividends or ...
Yes. Token balances, burn activity, trial updates, and ESG impact metrics will be published quarterly, with annual third-party audits and blockchain-verified data for transparency.
Personal data is stored only for the legally required period, then securely deleted. It is never repurposed for marketing or shared with third parties without consent.
The project enforces strict KYC/AML checks, complies with all relevant crypto and healthcare regulations, and follows medical advertising laws to avoid unverified claims.
GDT is structured as a utility token for service payments and participant rewards. It is designed to avoid classification as a security in all operating jurisdictions, with legal opinions obtained though lawyers in BVI, UAE, Japan, and the U.S.
The core ingredient, 5-ALA, is already widely available as a supplement with a strong safety profile. Biozipcode™ delivery aims to further minimize risks by targeting only diseased cells. However, full safety confirmation will come from ongoing clinical trials.
Patients will be able to join “Diabetes Cure Tours” in Palau, UAE, or Japan. These medical tourism programs combine treatment with long-term wellness stays and are paid for using GDT (or cash though GDT).
A Phase IIa trial has already shown significant improvement in patients with diabetes. The next step is to confirm complete remission in larger multi-country trials.
Unlike conventional treatments that focus on blood sugar management, this therapy aims to eliminate the root cause of diabetes—abnormal stem cells—offering the potential for complete remission.
Global Development Token (GDT) is issued by Auring Inc. (BVI) and operated by the Biozipcode Group, advancing curative diabetes research, medical tourism, and global healthcare innovation.
© 2023 – 2025 Global Development Token All Rights Reserved. | Powered by Studio Makyu Co., Ltd. & Biozipcode Group.
